MTOR and renal cell carcinoma: Currently, molecularly targeted therapeutics such as multi-targeted receptor tyrosine kinase (RTK) or mammalian target of rapamycin (mTOR) inhibitors are generally administered for patients with metastatic or recurrent RCC.